You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 2, February 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Invited Critique
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Colon Cancer
 •Oncology, Other
 •Radiation Therapy
 •Colorectal Surgery
 •Surgical Oncology
 •Prognosis/ Outcomes
 •Gastrointestinal Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer—Invited Critique

Harvey G. Moore, MD

Arch Surg. 2009;144(2):134-135.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Preoperative combined modality therapy (CMT) including radiation (50.40 Gy) and fluorouracil-based chemotherapy followed by radical resection is the preferred treatment paradigm for locally advanced (T3-T4 and/or N1-N2) rectal cancer in the United States.1 Castaldo et al report data from a large cohort of patients with rectal cancer from the SEER registry that corroborate the finding, previously noted in single- and multi-institution reports,2-3 that complete or near-complete pathologic responders to CMT have significantly improved OS and DSS compared with poor responders. Evidence suggests that decreased distant failure in complete responders may be largely responsible for this phenomenon.2-3 Taken together, these studies strongly suggest that primary tumor response to CMT may be a reliable surrogate for systemic control and long-term outcome. One must avoid the temptation, however, to interpret these data as license to be less aggressive in treating complete or near-complete responders. For instance, Castaldo and colleagues . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer
Eric T. Castaldo, Alexander A. Parikh, C. Wright Pinson, Irene D. Feurer, and Nipun B. Merchant
Arch Surg. 2009;144(2):129-134.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.